N

ewly published data reveal in greater depth the problem Sanofi Pasteur’s Dengvaxia vaccine poses to children who have never experienced a dengue infection.

The findings, first revealed by the company last November, were the basis of an April decision by a World Health Association expert panel to recommend the vaccine only be given to children who have tested positive for a prior dengue infection. There is no such test at the moment.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • I think that most people with a previous Denge infection would be able to remember it and get the vaccine without a test. My nephew got Denge when he was in India; it was like a hemorrhagic fever (bleeding and low platelet counts).

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy